CPhI China Pharma Connect is an online meeting appointment platform which provides you with a quick and effective way to manage your onsite meetings at CPhI & P-MEC China. You can use the system to make appointments in advance with 3,400+ exhibitors and 75,000+ of pre-registered visitors to optimize your visit and get the most out of your time onsite.
2.With China Pharma Connect system, you can:
► Search with multiple conditions: interest area, business nature, position, location, etc.
►Request meetings with potential partners, accept or cancel the requests from other clients.
►Choose time and place for meetings, and easily manage your meeting schedule.
►Book on-site meeting spaces in advance, with discounted rates and added value services.
►Receive emails on new meeting requests and status updates.
►Access online to the system from anywhere at any time, via mobiles, tablets, laptops and PCs, no need to download.
*In addition, as an exhibitor, you can also:
►Login with CPhI China Exhibitor E-manual account, automatically synchronize your company profile.
►Use the sub-accounts to manage the meetings of your company together with your colleagues.
3. Hot features of China Pharma Connect system:
►Precise targeting of potential suppliers & buyers.
►Efficient management of meetings.
►Easy access via PCs, tablets and mobile phones.
►On-site meeting spaces with lower prices.
►Meet with potential cooperative partner at the exhibition scene.
4. CPhI China Online Trading Matchmaking System will coming soon, stay tuned!
CPhI & P-MEC China 2020 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your One-stop Shop pharma platform in Asia.
Luye Pharma Group, an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications has entered a new partnership agreement with Distribution Solutions Phils., Inc. (Distriphil), a national pharmaceutical ...
Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) ...